Payment overview · 2025
General Payments
$505.91
13 reported records · 6 companies
Healthcare provider profile · identity verified
Christopher John Apostol, DO
Allopathic & Osteopathic Physicians|Family Medicine · EVANS, GA · NPI 1750383626
Verified facts
What the public records show
CMS Open Payments records show Christopher John Apostol, DO received $505.91 in general payments during 2025 across 13 reported records.
Sekisui Diagnostics LLC accounted for 59.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 304 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sekisui Diagnostics LLC | Unresolved — no canonical attribution shown | $300.00 | 59.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $103.13 | 20.4% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.04 | 9.1% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.23 | 5.4% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $15.84 | 3.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $13.67 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Gift | $300.00 | 1 |
| Food and Beverage | $205.91 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $103.13 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $103.13 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $103.13 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.04 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.04 | 3 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $27.23 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 304 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
304 | 304 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
97 | 80 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 942 | 281 |
| Amlodipine Besylate | Amlodipine Besylate | 622 | 192 |
| Levothyroxine Sodium | Levothyroxine Sodium | 495 | 146 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 462 | 148 |
| Lisinopril | Lisinopril | 459 | 137 |
| Hydrochlorothiazide | Hydrochlorothiazide | 370 | 113 |
| Losartan Potassium | Losartan Potassium | 340 | 110 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 304 | 304 |
| Omeprazole | Omeprazole | 301 | 90 |
| Metformin Hcl | Metformin Hcl | 288 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 63 |
| Simvastatin | Simvastatin | 211 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 52 |
| Gabapentin | Gabapentin | 157 | 48 |
| Carvedilol | Carvedilol | 156 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 28 |
| Trazodone Hcl | Trazodone Hcl | 148 | 38 |
| Jardiance | Empagliflozin | 135 | 37 |
| Sertraline Hcl | Sertraline Hcl | 133 | 32 |
| Metformin Hcl Er | Metformin Hcl | 124 | 40 |
| Eliquis | Apixaban | 117 | 25 |
| Potassium Chloride | Potassium Chloride | 113 | 37 |
| Glimepiride | Glimepiride | 109 | 34 |
| Meloxicam | Meloxicam | 109 | 41 |
| Allopurinol | Allopurinol | 108 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 24 |
| Januvia | Sitagliptin Phosphate | 99 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 29 |
| Furosemide | Furosemide | 98 | 32 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 97 | 80 |
| Famotidine | Famotidine | 94 | 35 |
| Ezetimibe | Ezetimibe | 92 | 30 |
| Benazepril Hcl | Benazepril Hcl | 91 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 35 |
| Atenolol | Atenolol | 88 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 19 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 85 | 85 |
| Montelukast Sodium | Montelukast Sodium | 79 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 22 |
| Ozempic | Semaglutide | 65 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 16 |
| Tramadol Hcl | Tramadol Hcl | 64 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 19 |
| Glipizide | Glipizide | 53 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Metolazone | Metolazone | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 15 |
| Finasteride | Finasteride | 45 | 12 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 12 |
| Bupropion Xl | Bupropion Hcl | 40 | 12 |
| Estradiol | Estradiol | 40 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 12 |
| Cefdinir | Cefdinir | 39 | 37 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 11 |
| Rybelsus | Semaglutide | 38 | 11 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 36 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 14 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 24 |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Azithromycin | Azithromycin | 21 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 11 |
| Primidone | Primidone | 21 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $505.91 · 13 records | Sekisui Diagnostics LLC | ABRYSVO, AREXVY, BEXSERO, CLOTTRIEVER BOLD CATHETER, COMIRNATY, Korlym, PREVNAR 20, SHINGRIX, WaveWriter Alpha Prime 16 | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error